We are a team of scientists, innovators and entrepreuners

Dr. Danuta Jeziorska

Academic Founder, Executive Director & CEO

Danuta is a Founder and CEO of Nucleome Therapeutics and an Honorary Senior Scientist at the University of Oxford. Previously, she co-founded Innovation Forum Oxford, for which she was recognised as one of the Movers and Shakers in BioBusiness in 2018. Her scientific expertise lies in decrypting how genes are regulated, a field which she has been working on over the last 14 years.

Prof. Jim Hughes

Academic Founder, Non-Executive Director

Jim is a Founder of Nucleome Therapeutics and a Professor of Gene Regulation at the University of Oxford. His research combines experimental, computational and machine learning based approaches in order to functionally interpret the non-coding genome and its role in human diseases. His group has developed numerous cutting-edge technologies and tools used world-wide.

Dr. James Davies

Academic Founder

James is a Founder of Nucleome Therapeutics and Associated Professor at the University of Oxford. His expertise lies in developing novel sequencing-based assays and computational approaches for understanding how the genome functions. He is also a consultant haematologist with an interest in stem cell transplantation and cellular therapy and a fully qualified intensive care physician

Dr. Danuta Jeziorska

Academic Founder, Executive Director & CEO

Danuta is a Founder and CEO of Nucleome Therapeutics and an Honorary Senior Scientist at the University of Oxford. Previously, she co-founded Innovation Forum Oxford, for which she was recognised as one of the Movers and Shakers in BioBusiness in 2018. Her scientific expertise lies in decrypting how genes are regulated, a field which she has been working on over the last 14 years.

Prof. Jim Hughes

Academic Founder, Non-Executive Director

Jim is a Founder of Nucleome Therapeutics and a Professor of Gene Regulation at the University of Oxford. His research combines experimental, computational and machine learning based approaches in order to functionally interpret the non-coding genome and its role in human diseases. His group has developed numerous cutting-edge technologies and tools used world-wide.

Dr. Jonathan Hepple

Non-Executive Director & OSI Advisor

Jon is a co-founder of Rosetta Capital Limited, a venture capital firm focused on life science and medical technology sectors, where he has served as a Partner since January 2009. He has more than twenty years of investment experience in the life sciences industry. He started his investment career at Rothschild Asset Management before co-founding BioScience Managers Ltd in 2001. He has also served as a partner of Seroba Life Sciences Limited. Dr Hepple has held board director and observer roles in portfolio companies such as Aprea Therapeutics, Covagen AG, Opsona Therapeutics Ltd., Catalyst Biosciences, Glycomimetics, Inc., NovImmune SA and Tranzyme Pharma. He received his PhD from Cambridge University for cancer research.

Dr. James Davies

Academic Founder

James is a Founder of Nucleome Therapeutics and Associated Professor at the University of Oxford. His expertise lies in developing novel sequencing-based assays and computational approaches for understanding how the genome functions. He is also a consultant haematologist with an interest in stem cell transplantation and cellular therapy and a fully qualified intensive care physician

Matt Carpenter

Observer

Matt obtained a first-class honours degree in Biomedical Sciences from the University of the West of England, Bristol and subsequently a PhD from Imperial College in immunology (1999). Following three years as a post-doctoral research fellow at Imperial College, and a short spell as a technical adviser with Invitrogen, Matt entered the technology transfer profession in 2004 as the Intellectual Property Rights Manager within the Research and Knowledge Exchange Services at the University of Strathclyde, Glasgow. Matt joined Oxford University Innovation in 2011 and is currently a Principal Licensing & Ventures Manager (pharma and biotech team) in the Licensing & Ventures Team.

Dr. Eliot Forster

CEO of F-Star, former CEO of Immunocore

Eliot has more than 28 years of experience in the pharmaceutical and biotechnology industry and previously served as Chief Executive Officer of Immunocore, Creabilis Therapeutics and Solace Pharmaceuticals. Other previous roles included Head of Development and Operations for the EU and Asia at Pfizer. Eliot has held a number of non-executive Director roles and is currently non-executive Chairman of Avacta plc. He is an Honorary Visiting Professor of the Pharmacology and Physiology Department at the University of Liverpool and an Honorary Professor at the University of Pavia, a Board member of OSCHR (Office for Strategic Coordination of Health Research) and the National Genomics Board. He holds a PhD from University of Liverpool and an MBA from Henley Management College.

Raymond Barlow BSc, PhD, MBA

CEO of SynOx Therapeutics

Ray has over 20 years’ experience of the biopharmaceutical industry gained through leadership positions in scientific, clinical, commercial, and executive roles. Ray has diverse experience gained in global pharmaceutical companies (AstraZeneca, J&J and Amgen), publicly listed biotech’s (Emergent BioSolutions Inc, Crucell NV, e-Therapeutics PLC and Kiadis NV) and private companies such as Asterion Limited.
Ray has very strong corporate development experience, right across the value chain and has led and closed numerous M&A, licensing, commercial, manufacturing, equity-based and IP-based deals collectively worth multiple billions of dollars. Prior to his industrial career, Ray completed a PhD at Manchester University, UK and did postdoctoral research at McGill University, Canada.

Rene Russo, BSc, PhD

CEO – Xilio Therapeutics

Dr. Russo is an accomplished biotechnology CEO with over 20 years of experience leading R&D and commercialization in the biopharmaceutical industry. As an executive leader, Dr. Russo has been responsible for early preclinical research through all phases of clinical development, registration, and commercialization of many successful therapies in the US and EU. She is currently the CEO of Xilio Therapeutics, a privately held immuno-oncology company focused on the development of tumor-selective, potent IO therapeutics. Prior to Xilio, Dr. Russo was the President and CEO of Arsanis (NASDAQ: ASNS), a company developing monoclonal antibodies to prevent and treat serious infectious diseases, merged with X4 Pharmaceuticals (NASDAQ: XFOR) in 2018. Prior to Arsanis, Dr. Russo spent 12 years at Cubist Pharmaceuticals (NASDAQ: CBST), a leading global anti-infective company (acquired by Merck for $9.6B). At Cubist, she contributed to the successful launch and commercialization of Cubicin (reaching over $1B in sales annually worldwide) and played a key role in the successful integration of two public companies, Optimer Pharmaceuticals (NASDAQ: OPTR) and Trius Therapeutics (NASDAQ: TSRX). Prior to Cubist, Dr. Russo held R&D roles at Bristol-Myers Squibb (NYSE: BMY) contributing to the successful development and global commercialization of several therapies including Reyataz and Baraclude. Dr. Russo is cofounder and chairman of the board of Adagio Therapeutics (NASDAQ: ADGI) and serves on the boards of Xilio Therapeutics, X4 Pharmaceuticals (NASDAQ: XFOR), Celsius Therapeutics, and Life Science Cares. Dr. Russo holds a B.S. in pharmacy and a Doctor of Pharmacy degree from Rutgers University and completed a post- doctoral fellowship in infectious diseases with Bristol-Myers Squibb.

Chas Bountra, PhD.

Pro-Vice Chancellor for Innovation and Professor of Translational Medicine at the University of Oxford. Director of the Centre for Medicines Discovery in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology.

Chas is the Director of the newly created Centre for Medicines Discovery, he is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.
Prior to coming back to Oxford in 2008, Chas was Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of >40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. More than 20 of these molecules progressed into patient studies and >5 of these delivered successful “Proof of Concept” data and hence progressed into late-stage development. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1 antagonists are anti-emetic in preclinical and clinical studies. As Director of SGC-Oxford (2008 - mid 2020) he established a leading research group in human protein structural biology and epigenetics chemical biology, and arguably one of the most successful open innovation, public-private partnerships in the world.